Literature DB >> 25355797

Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.

Gerald Aichinger1, Barbara Grohmann-Izay2, Maikel V W van der Velden2, Sandor Fritsch3, Manuela Koska3, Daniel Portsmouth4, Mary Kate Hart5, Wael El-Amin5, Otfried Kistner4, P Noel Barrett4.   

Abstract

Studies on candidate pandemic vaccines against avian influenza viruses have focused on H5N1, but viruses of other subtypes, such as A/H9N2, are also considered to have pandemic potential. We investigated the safety and immunogenicity of two immunizations with one of five different antigen doses (ranging from 3.75 to 45 μg of hemagglutinin antigen) of a nonadjuvanted whole-virus G9 lineage H9N2 influenza virus vaccine in healthy adults aged 18 to 49 years. The antibody responses were measured by hemagglutination inhibition (HI), microneutralization (MN), and single radial hemolysis (SRH) assays. To investigate a hypothesis that previous exposure to H2N2 viruses in subjects born in or before 1968 might prime for more robust antibody responses to H9N2 vaccination than that in subjects born after 1968, a post hoc age-stratified analysis of antibody responses was done. Both vaccinations in all dose groups were safe and well tolerated. No vaccine-related serious adverse events were reported, and the majority of the adverse reactions were rated as mild. The rates of injection site reactions were lower in the 3.75-μg- and 7.5-μg-dose groups than those in the higher-dose groups; the rates of systemic reactions were similar across all dose groups. The seroprotection rates among the different dose groups 21 days after the second immunization ranged from 52.8% to 88.9% as measured by HI assay, from 88.7% to 98.1% or 82.7% to 96.2% as measured by MN assay (MN titer cutoffs, 1:40 and 1:80, respectively), and from 94.2% to 100% as measured by SRH assay. Higher antibody responses were not induced in subjects born in or before 1968. These data indicate that a nonadjuvanted whole-virus H9N2 vaccine is well tolerated and immunogenic in healthy adults. (This study has been registered at ClinicalTrials.gov under registration no. NCT01320696.).
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25355797      PMCID: PMC4278922          DOI: 10.1128/CVI.00275-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  46 in total

1.  A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

Authors:  Hartmut J Ehrlich; Markus Müller; Sandor Fritsch; Markus Zeitlinger; Greg Berezuk; Alexandra Löw-Baselli; Maikel V W van der Velden; Eva Maria Pöllabauer; Friedrich Maritsch; Borislava G Pavlova; Paul A Tambyah; Helen M L Oh; Emanuele Montomoli; Otfried Kistner; P Noel Barrett
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

2.  Response to a monovalent 2009 influenza A (H1N1) vaccine.

Authors:  Michael E Greenberg; Michael H Lai; Gunter F Hartel; Christine H Wichems; Charmaine Gittleson; Jillian Bennet; Gail Dawson; Wilson Hu; Connie Leggio; Diane Washington; Russell L Basser
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245

3.  Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.

Authors:  Karl G Nicholson; Catherine I Thompson; Jaco M Klap; John M Wood; Sally Batham; Robert W Newman; Robert Mischler; Maria C Zambon; Iain Stephenson
Journal:  Vaccine       Date:  2009-09-30       Impact factor: 3.641

4.  Poultry carrying H9N2 act as incubators for novel human avian influenza viruses.

Authors:  Di Liu; Weifeng Shi; George F Gao
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

5.  Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

Authors:  Timo Vesikari; Aino Karvonen; Sandrine Tilman; Astrid Borkowski; Emanuele Montomoli; Angelika Banzhoff; Ralf Clemens
Journal:  Pediatrics       Date:  2010-09-06       Impact factor: 7.124

Review 6.  Developing cell culture-derived pandemic vaccines.

Authors:  P Noel Barrett; Daniel Portsmouth; Hartmut J Ehrlich
Journal:  Curr Opin Mol Ther       Date:  2010-02

7.  Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

Authors:  Terry Nolan; Jodie McVernon; Maryanne Skeljo; Peter Richmond; Ushma Wadia; Stephen Lambert; Michael Nissen; Helen Marshall; Robert Booy; Leon Heron; Gunter Hartel; Michael Lai; Russell Basser; Charmaine Gittleson; Michael Greenberg
Journal:  JAMA       Date:  2009-12-21       Impact factor: 56.272

8.  A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.

Authors:  Otfried Kistner; Brian A Crowe; Walter Wodal; Astrid Kerschbaum; Helga Savidis-Dacho; Nicolas Sabarth; Falko G Falkner; Ines Mayerhofer; Wolfgang Mundt; Manfred Reiter; Leopold Grillberger; Christa Tauer; Michael Graninger; Alois Sachslehner; Michael Schwendinger; Peter Brühl; Thomas R Kreil; Hartmut J Ehrlich; P Noel Barrett
Journal:  PLoS One       Date:  2010-02-23       Impact factor: 3.240

9.  Minimal molecular constraints for respiratory droplet transmission of an avian-human H9N2 influenza A virus.

Authors:  Erin M Sorrell; Hongquan Wan; Yonas Araya; Haichen Song; Daniel R Perez
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-20       Impact factor: 11.205

10.  A novel genotype H9N2 influenza virus possessing human H5N1 internal genomes has been circulating in poultry in eastern China since 1998.

Authors:  Pinghu Zhang; Yinghua Tang; Xiaowen Liu; Wenbo Liu; Xiaorong Zhang; Hongqi Liu; Daxin Peng; Song Gao; Yantao Wu; Luyong Zhang; Shan Lu; Xiufan Liu
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

View more
  4 in total

1.  Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques.

Authors:  Brendon Y Chua; Toshiki Sekiya; Marios Koutsakos; Naoki Nomura; Louise C Rowntree; Thi H O Nguyen; Hayley A McQuilten; Marumi Ohno; Yuki Ohara; Tomohiro Nishimura; Masafumi Endo; Yasushi Itoh; Jennifer R Habel; Kevin J Selva; Adam K Wheatley; Bruce D Wines; P Mark Hogarth; Stephen J Kent; Amy W Chung; David C Jackson; Lorena E Brown; Masashi Shingai; Katherine Kedzierska; Hiroshi Kida
Journal:  PLoS Pathog       Date:  2022-10-07       Impact factor: 7.464

2.  Refining the approach to vaccines against influenza A viruses with pandemic potential.

Authors:  Rita Czako; Kanta Subbarao
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

Review 3.  Emerging Influenza Strains in the Last Two Decades: A Threat of a New Pandemic?

Authors:  Claudia Trombetta; Simona Piccirella; Daniele Perini; Otfried Kistner; Emanuele Montomoli
Journal:  Vaccines (Basel)       Date:  2015-03-18

Review 4.  Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs.

Authors:  Nikolai Petrovsky
Journal:  Drug Saf       Date:  2015-11       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.